from david stat com david dodel subject hicn medic news part repli to david stat com david dodel distribut world organ stat gateway servic wb tpi line cut volum number april health info com network medic newslett editor david dodel north nd street suit scottsdal arizona usa telephon fax compil copyright david dodel all right reserv licens herebi grant republish electron media fee charg long text copyright notic licens are attach intact republish portion portion the health info com network newslett distribut biweekli articl on medic natur welcom if articl pleas contact the editor inform submit it if interest join autom distribut system pleas contact editor mail address editor internet david stat com fidonet bitnet atw asuacad listserv mednew asuacad bitnet or internet mednew asuvm inr asu edu anonym ftp vm nodak edu notif list hicn notifi request stat com fax deliveri contact editor inform center diseas control prevent mmwr april rate cesarean deliveri malaria among embassi personnel fda approv hib vaccin children infant dental news workshop explor oral manifest hiv infect food drug administr news fda approv depo provera inject contracept new rule speed approv drug life threaten ill articl research promis prevent slow blind retin diseas affluent diet increas risk of heart diseas gener announc public health profession nation cancer institut public patient avail nation cancer institut aid news summari aid daili summari april april aid statist worldwid aid statist hicnet medic newslett page volum number april center diseas control prevent mmwr rate cesarean deliveri unit state sourc mmwr date apr cesarean deliveri account nearli million approxim million annual deliveri unit state sinc tabl the cesarean rate unit state third highest among report countri exceed brazil puerto rico thi report present data cesarean deliveri cdc nation hospit discharg survey nhd compar data previou year data discharg short stay nonfeder hospit collect annual sinc nhd conduct cdc nation center for health statist for medic demograph inform abstract sampl inpati discharg particip hospit the cesarean vagin birth prior cesarean vbac present report base weight nation estim nhd sampl approxim women discharg after deliveri the estim number live birth type deliveri calcul appli cesarean rate nhd live birth nation vital registr data therefor estim number cesarean report agre previous publish data base sole nhd state differ analysi signific the confid level base two tail test critic valu of in cesarean per deliveri rate in similar rate tabl the primari cesarean rate number first cesarean per deliveri women previou cesarean also stabl rang in cesarean rate south significantli higher rate west midwest northeast rate higher mother age greater equal year than younger women proprietari hospit nonprofit govern hospit hospit fewer bed larger hospit deliveri blue cross blue shield privat insur expect sourc payment sourc payment tabl the pattern character primari cesarean deliveri sinc earli number percentag birth older women increas howev age distribut mother remain the overal cesarean rate would essenti observ base nhd approxim live birth hicnet medic newslett page volum number april estim cesarean deliveri of these estim birth repeat cesarean primari cesarean sinc approxim primari cesarean perform annual in women previou cesarean deliv vagin compar of cesarean associ previou cesarean dystocia failur labor progress breech present fetal distress specifi complic the averag hospit stay deliveri day in comparison hospit stay primari cesarean deliveri day and repeat cesarean day nearli twice durat vbac deliveri day vagin deliveri vbac day in averag hospit stay deliveri day primari cesarean day repeat cesarean day vbac non vbac vagin deliveri day respect report by offic vital health statist system nation center for health statist cdc editori note the cesarean rate unit state steadili increas howev find report indic rate have stabl sinc becaus littl evid matern child health statu improv time cesarean associ increas risk complic childbirth nation health object year reduc overal cesarean rate fewer per deliveri primari cesarean rate fewer per deliveri object postpartum complic includ urinari tract wound infect may account part longer hospit stay cesarean deliveri than vagin birth moreov prolong hospit stay cesarean deliveri substanti increas health care cost for exampl averag cost cesarean vagin deliveri respect the addit cost cesarean deliveri includ physician fee hospit charg if cesarean rate the year object instead number of cesarean birth would decreas versu result save billion physician fee hospit charg despit steadi increas vbac rate sinc sever factor may imped progress toward year nation health object cesarean deliveri for exampl vbac rate substanti reflect number women offer trial labor increasingli encourag sinc of women offer trial labor could deliv vagin level alreadi achiev mani hospit trial labor routin offer hospit survey the recent year hicnet medic newslett page volum number april nation data avail vbac rate accord nhd data wa the year object specifi vbac rate base women prior cesarean regardless whether trial labor attempt to reach overal cesarean rate goal howev increas vbac rate need combin substanti reduct primari rate one hospit succeed reduc rate cesarean deliveri appli object criteria four common indic cesarean deliveri requir second opinion institut peer review process other recommend decreas cesarean deliveri rate includ elimin incent physician hospit equal reimburs vagin cesarean deliveri public dissemin physician hospit specif cesarean deliveri rate increas public awar differ practic address malpractic concern which may import factor maintain high rate cesarean deliveri refer notzon fc intern differ use obstetr intervent jama grave ej nch summari nation hospit discharg survey hyattsvil maryland us depart health human servic public health servic cdc advanc data no taffel sm placek pj kosari cl cesarean section rate updat birth public health servic healthi peopl nation health promot diseas prevent object full report commentari washington dc us depart health human servic public health servic dhh public no ph danforth dn cesarean section jama hospit insur associ america tabl cost matern care physician fee hospit charg censu region base consum price index in sourc book health insur data washington dc hospit insur associ america committe obstetr acog committe opinion no guidelin vagin deliveri previou cesarean birth washington dc american colleg obstetrician gynecologist hicnet medic newslett page volum number april rosen mg dickinson jc vagin birth cesarean meta analysi indic success obstet gynecol shiono ph fielden jg mcnelli rhoad gg pears wh recent trend cesarean birth trial labor rate unit state jama myer sa gleicher success program lower cesarean section rate engl med use trade name commerci sourc identif doe impli endors public health servic depart of health human servic hicnet medic newslett page volum number april malaria among embassi personnel kampala uganda sourc mmwr date apr the treatment prevent malaria africa becom challeng complex problem increas drug resist although risk acquir malaria citizen depend station oversea gener low risk vari substanti unpredict dure may offic medic servic depart state om do cdc notifi increas number malaria case among offici personnel station kampala uganda review health record embassi health unit ehu kampala indic case malaria diagnos offici personnel march june compar two case period ehu om do cdc conduct investig confirm report malaria case identifi potenti risk factor malaria among embassi personnel thi report summar result investig malaria blood smear report case patient avail review om do cdc case malaria confirm the slide posit plasmodium sp of person slide confirm malaria questionnair distribut person serv ehu obtain inform resid activ use malaria use person protect measur use bednet and insect repel window door screen wear long sleev pant even of person elig survey respond risk malaria associ sex locat resid kampala although risk malaria higher among children age less than equal year among person greater year differ signific rel risk rr confid interv ci eighti two percent case occur among person live kampala year compar live less year travel outsid kampala area rural set associ increas risk malaria four malaria regimen use person particip survey mefloquin chloroquin proguanil chloroquin alon proguanil alon in addit person respond not use malaria the risk malaria significantli lower among person use either mefloquin chloroquin proguanil among person use regimen prophylaxi rr ci twelv person use prophylaxi report side effect fear possibl side effect reason the risk malaria lower among person report use bednet hicnet medic newslett page volum number april all time among person sometim rare use bednet rr ci the risk malaria also lower among person consist use insect repel even compar rare use repel rr upper confid limit risk malaria associ failur window door screen wear long sleev pant even as result investig ehu staff review personnel the need use compli recommend malaria regimen ehu staff also emphas need use person protect measur made plan obtain insecticid impregn bednet provid window door screen personnel report by embassi health unit kampala uganda offic medic svc dept state washington malaria br div parasit diseas nation center infecti diseas cdc editori note in uganda increas malaria among personnel attribut poor adher recommend malaria regimen use person protect measur period increas malaria transmiss intensifi chloroquin resist sub saharan africa the find report underscor need provid initi continu counsel regard malaria prevent person live abroad malaria endem area prevent measur also import short term travel area mefloquin effect prophylaxi regimen africa other area chloroquin resist falciparum howev area thailand resist mefloquin may limit effect in africa efficaci mefloquin compar chloroquin alon prevent infect falciparum mefloquin safe well toler given mg per week year period the risk for seriou advers reaction possibl associ mefloquin prophylaxi psychosi convuls low episod per user risk less sever advers reaction dizzi complaint sleep disturb similar other antimalari doxycyclin similar prophylact efficaci mefloquin need for daili dose may reduc complianc effect regimen chloroquin alon effect prophylaxi area intens chloroquin resist southeast asia africa in africa person cannot take mefloquin doxycyclin chloroquin proguanil is altern although less effect regimen chloroquin use malaria prevent area chloroquin resist falciparum report countri specif recommend prevent malaria inform hicnet medic newslett page volum number april on dosag precaut malaria regimen avail health inform intern travel yellow book hour day telephon fax refer lobel ho miani eng et al long term malaria prophylaxi weekli mefloquin peac corp volunt effect well toler regimen lancet world health organ review central nervou system advers event relat antimalari drug mefloquin geneva world health organ public no who mal pang limsomwong singharaj prophylact treatment vivax falciparum malaria low dose doxycyclin infect di pang limsomwong boudreau ef singharaj doxycyclin prophylaxi falciparum malaria lancet cdc health inform intern travel atlanta us depart health human servic public health servic dhh public no cdc hicnet medic newslett page volum number april fda approv use new haemophilu conjug vaccin combin diphtheria tetanu pertussi haemophilu conjug vaccin infant children sourc mmwr date apr haemophilu influenza type hib conjug vaccin recommend use infant sinc routin use infant vaccin contribut substanti declin incid hib diseas unit state vaccin diphtheria tetanu pertussi infanc childhood administ routin unit state sinc late associ greater reduct morbid mortal associ infect organ becaus increas number vaccin routin recommend infant high prioriti develop combin vaccin allow simultan administr fewer separ inject the food drug administr fda recent licens two new product for vaccin children diseas haemophilu conjug vaccin tetanu toxoid conjug acthib trademark vaccin hib diseas combin diphtheria tetanu toxoid whole cell pertussi vaccin dtp hib conjug vaccin tetramun trademark combin vaccin formul use vaccin children diphtheria tetanu pertussi hib diseas acthib trademark on march fda approv new haemophilu conjug vaccin phosphat tetanu toxoid conjug prp manufactur pasteur merieux serum et vaccin distribut acthib trademark connaught laboratori inc swiftwat pennsylvania thi vaccin licens use infant three dose primari vaccin seri administ age month previous unvaccin infant month age receiv two dose month apart previous unvaccin children month age receiv one dose booster dose administ month age recommend children previous unvaccin children month age receiv singl dose requir booster more infant receiv primari vaccin seri acthib trademark consecut dose and month age develop geometr mean titer anti haemophilu polysaccharid antibodi greater ug ml thi respons similar that infant receiv recommend seri previous licens haemophilu conjug vaccin efficaci demonstr prospect trial two efficaci trial prp termin earli becaus concomit licensur haemophilu conjug vaccin hicnet medic newslett page volum number april for use infant in studi case invas hib diseas were detect approxim infant vaccin prp these other studi suggest efficaci prp vaccin similar that licens hib vaccin tetramun trademark on march fda approv combin diphtheria tetanu toxoid whole cell pertussi vaccin dtp haemophilu conjug vaccin tetramun trademark avail lederl praxi biolog pearl river new york combin two previous licens product dtp triimmunol regist manufactur lederl laboratori pearl river new york haemophilu conjug vaccin hibtit regist manufactur praxi biolog inc rochest new york thi vaccin licens use children age month year for protect diphtheria tetanu pertussi hib diseas indic vaccin dtp vaccin haemophilu conjug vaccin coincid base demonstr co mparabl higher antibodi respons compon two vaccin tetramun trademark is expect provid protect hib well diphtheria tetanu and pertussi equival alreadi licens formul dtp haemophilu vaccin the advisori committe immun practic acip recommend all infant receiv primari seri one licens haemophilu conjug vaccin begin month age booster dose age month the acip also recommend infant receiv four dose primari seri diphtheria tetanu toxoid pertussi vaccin month age booster dose year complet statement regard recommend use acthib trademark tetramun trademark develop report by offic vaccin research review center biolog evalu research food drug administr div immun nation center prevent svc mening special pathogen br div of bacteri mycot diseas nation center infecti diseas cdc refer adam wg deaver ka cochi sl et al declin childhood haemophilu influenza type hib diseas hib vaccin era jama broadhurst le erickson rl kelley pw decreas invas haemophilu influenza diseas armi children jama murphi tv white ke pastor et al declin incid haemophilu influenza type diseas sinc introduct vaccin jama hicnet medic newslett page volum number april fritzel plotkin efficaci safeti haemophilu influenza type capsular polysaccharid tetanu protein conjug vaccin pediatr acip haemophilu conjug vaccin prevent haemophilu influenza type diseas among infant children two month age older recommend immun practic advisori committe acip mmwr no rr acip diphtheria tetanu pertussi recommend vaccin use and prevent measur recommend immun practic advisori committe acip mmwr no rr acip pertussi vaccin acellular pertussi vaccin reinforc and booster use supplementari acip statement recommend immun practic advisori committe acip mmwr no rr acip pertussi vaccin acellular pertussi vaccin fourth fifth dose dtp seri updat supplementari acip statement recommend immun practic advisori committe acip mmwr no rr use trade name commerci sourc identif doe impli endors public health servic depart of health human servic hicnet medic newslett page volum number april dental news intern workshop explor oral manifest of hiv infect nidr research digest written jodi dove march nation institut dental research at second intern workshop oral manifest hiv infect held januari februari san francisco particip explor issu relat epidemiolog basic molecular virolog mucos immunolog oral clinic present hiv infect the workshop organ dr john greenspan dr deborah greenspan depart stomatolog school dentistri univers california san francisco an intern steer committe scientif program committe provid guidanc the confer drew scientist countri includ asia africa europ central america south america well unit state canada support tor workshop provid nation institut dental research nation cancer institut nation institut allergi infecti diseas nih offic aid research and procter gambl compani among topic discuss were epidemiolog hiv lesion ethic profession respons public polici occup issu provis of oral care hiv posit popul salivari hiv transmiss mucos immun opportunist infect pediatr hiv infect women issu recommend recommend emerg workshop defin associ between appear oral lesion rate progress hiv establish univers terminolog hiv associ oral lesion look more effect treatment oral manifest expand molecular biolog studi understand relationship hiv infect common oral lesion studi effect hiv therapi oral lesion epidemiolog sinc first intern workshop oral manifest hiv infect conven five year ago epidemiolog hiv infect hicnet medic newslett page volum number april radic chang in hiv infect detect report larg in homosexu bisexu male intraven drug user hemophiliac today hiv infect seen heterosexu male femal children adolesc while predomin impact hiv infect felt africa major increas infect rate seen southeast asia well five hundr thousand case report date region are appear time research continu document epidemiolog oral lesion such hairi leukoplakia candidiasi they also begin explor the relationship specif oral lesion hiv diseas progress and prognosi social polit issu discuss social polit implic hiv infect focus chang public attitud aid retribut indiscrimin sexual behavior drug use speaker also address health care deliveri hiv infect patient need educ public about aid is acquir saliva salivari gland confer speaker describ transmiss issu hiv inhibitori activ saliva strength vari among differ salivari secret whole saliva greater inhibitori effect submandibular secret turn greater inhibitori effect parotid secret research shown least two mechan respons for salivari inhibitori activ they attribut hiv inhibitori effect of saliva aggreg agglutin hiv saliva may promot clearanc viru prevent reach target cell direct effect viru target cell other topic discuss manifest salivari gland diseas in hiv infect person current research oral mucos immun pediatr issu pediatr aid recent emerg area intens interest with earli accur diagnosi proper treatment life expect hiv infect children tripl the prevent transmiss hiv mother child may possibl mani case particularli mother sero statu known prior give birth periodont gingiv tissu diseas hicnet medic newslett page volum number april oral health research continu explor periodont diseas gingiv found individu hiv infect recommend made the workshop includ standard terminolog refin diagnost marker standard studi design proper consider of confound variabl result periodont therapi occup treatment issu occup issu surround treatment hiv infect individu and treatment render hiv infect health care profession still command consider attent factor consider includ cost benefit of hiv test patient to health care provid transmiss hiv infect and revers use mainstream versu dedic facil treatment hiv infect patient confer particip anticip third intern workshop the oral manifest hiv infect held five year less proceed second workshop publish quintess compani late end part internet david stat com fax bitnet atw asuacad fidonet amateur packet ax wb tpi wb tpi az usa na